Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Leukemia, Myeloid, Acute 12Leukemia, Myelomonocytic, Acute 5Leukemia, Monocytic, Acute 5Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Lymphoma 3Leukemia, Promyelocytic, Acute 3Congenital Abnormalities 3Leukemia, Biphenotypic, Acute 2Neutropenia 1Lymphatic Diseases 1Leukemia, Myeloid 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Dendritic Cell Sarcoma, Interdigitating 1Breast Neoplasms 1

Interventions

amonafide 1Daunorubicin 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphatic Diseases × Daunorubicin × Clear all
NCT00715637 2010-10-13

Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study

Antisoma Research

Phase 3 Unknown
420 enrolled
Other hematologic neoplasm

Leukemia, Lymphatic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡